Efficacy and safety of trabectedin as an early treatment for advanced or metastatic liposarcoma and leiomyosarcoma. (January 2014)

• Record Type: Journal Article
• Authors: Blay, Jean Yves; Casali, Paolo; Nieto, Antonio; Tanović, Adnan; Cesne, Axel Le
• Is Part Of: Future oncology. Volume 10:Number 1(2014)
• Page Start: 59
• Page End: 68
• Publication Date: 2014-01
• Subjects: leiomyosarcoma -- liposarcoma -- sarcoma -- second-line treatment -- STS -- trabectedin; Oncology -- Periodicals; 616.99405
• DOI: 10.2217/fon.13.163
• Languages: English
• ISSNs: 1479-6694

Abstract

ABSTRACT: Aims: We aimed to evaluate the effect of prior chemotherapies on the outcomes of patients with liposarcoma and leiomyosarcoma treated with trabectedin as a 24-h infusion every 3 weeks.Patients & methods: Data from 129 patients who received trabectedin as second-line treatment following failure with an anthracycline/ifosfamide and those who had received at least two lines of prior chemotherapy were analyzed.Results: Forty seven patients received one prior regimen (group A) and 82 patients received at least two lines of chemotherapy (group B). A favorable trend in median time to progression (4.4 vs 3.0 months), progression-free survival (4.4 vs 2.6 months) and overall survival (17.4 vs 13.3 months) was found in group A. A trend toward higher overall response rate (6.4 vs 4.9%) and disease control rate (34.0 vs 26.8%) also favored group A. Both groups had equivalent safety profiles.Conclusion: All efficacy outcomes were better in patients who received trabectedin as second-line treatment compared with patients with more extensive prior therapy.